Rituximab Monotherapy for Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis and Chronic Active Epstein-Barr Virus Infection With Only and Mainly B Lymphocytes of EBV Infection

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT05384743

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:38:39.232422+00:00

Published At

2022-05-20T00:00:00+00:00

Record Updated At

2022-05-20

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Secondary Hemophagocytic Lymphohistiocytosis", "Chronic Active Epstein-Barr Virus Infection"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2022-05-20"

protocolSection.identificationModule.nctId

"NCT05384743"

protocolSection.identificationModule.officialTitle

"Rituximab Monotherapy for Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis and Chronic Active Epstein-Barr Virus Infection With Only and Mainly B Lymphocytes of EBV Infection"

protocolSection.statusModule.overallStatus

"UNKNOWN"

protocolSection.designModule.phases

["PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Secondary Hemophagocytic Lymphohistiocytosis (protocolSection.conditionsModule.conditions)
• Chronic Active Epstein-Barr Virus Infection (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.